Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of precision medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age-related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Apr 13, 2022

Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the pharmacology known as allosteric modulation. This emerging class of small molecule drugs known as allosteric modulators is being explored for treating central nervous system and neurologic disorders, particularly movement disorders like dyskinesia associated with Parkinson's and dystonia. Addex did not invent allosteric modulation but is pioneering the screening technologies to find these difficult to locate molecules.

Tim explains, "In the conventional world, which people probably know a lot about, are the orthosteric agonists and antagonists. These molecules are binding to the active site. The way to understand, in simple terms, the difference between an allosteric and an orthosteric drug is to use an analogy of the dimmer light switch."

"If you think about the dimmer light switch, you're initially turning the light on-- that would be the orthosteric agonist. Turning the light off would be the orthosteric antagonist, and what Addex is, is the dimmer. We leave the body in charge of turning the light on, so to speak, and then the Addex, allosteric modulator, if it's a positive modulator, we are really turning up the intensity of the light. If it is a negative modulator, we are turning down the intensity, so we're really modulating the intensity of the signal."

@AddexPharma #AllostericModulators #CNSDrugDiscovery #NeurologicDrugDiscovery #DrugDevelopment #ParkinsonsDisease #Dyskinesia #Dystonia #Blepharospasm #MovementDisorders

Addextherapeutics.com

Listen to the podcast here

 

Addex